Sweden-based venture capital firm Industrifonden sold 3 million Oncopeptides AB (publ) shares to institutional investors.
The shares sold represent about 5.4% of Oncopeptides' existing share capital and voting rights. Oncopeptides said it will not receive any proceeds from the transaction.
As a result of the transaction, Industrifonden now owns 7,420,805 Oncopeptides shares, or about 13.4% of the Swedish pharmaceutical company's existing share capital.
Financial details of the transaction were not disclosed.
Jefferies International Ltd. was the sole book runner for the transaction.
